\
Medical Advocates
Enfuvirtide [T-20] (Fuzeon)
 
Main Page

New and Noteworthy
 Corporate Fuzeon Web
 Database of ARV Drug Interactions
 Guidelines
FDA Fuzeon Updates
 Journal Data
 Conference Data
Perinatal  Data
 Pediatric Data
Biojector Needle-Free Injection Device
Terumo SurGuard
 
ARV Drugs Main Page Main New/Newsworthy Home Page      
This web page is best viewed by using INTERNET EXPLORER
Last Update:  July 09, 2010
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Read
New and Noteworthy
     
June 2010
 
FDA Fuzeon Warnings/Label Changes
       
Perinatal Data
       
Guidelines and Recommendations
 
     United States

          Internet Documents

  FULL TEXT PDF DOCUMENT
 Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  FULL TEXT PDF DOCUMENT
 Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
   
  Journal Papers, Abstracts and Commentates
 
 
FULL-TEXT ARTICLE
 HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and
Lymphocyte Membranes.
 Matos PM, Castanho MA, Santos NC.
PLoS One. 2010 Mar 23;5(3):e9830
 Paper

Use of enfuvirtide in pregnancy in HIV positive women in seven cases.
Jeantils V, Alloui C, Rodrigues A, et al
 Gynecol Obstet Fertil. 2009 Apr 22.
 Abstract

Use of darunavir and enfuvirtide in a pregnant woman.
 Sued O, Lattner J, Gun A, Patterson P, et al  
Int J STD AIDS. 2008 Dec;19(12):866-7.
 Abstract
 
Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide
use in late pregnancy.
 Madeddu G, Calia GM, Campus ML, et al 
Int J STD AIDS. 2008 Sep;19(9):644-5.
 Abstract

Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model.
 Ceccaldi PF, Ferreira C, Gavard L, et al
 Am J Obstet Gynecol. 2008 Jan 31
Abstract

Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with
virological breakthrough.
 Meyohas M-C, Lacombe M, Carbonne B, et al
 AIDS. 18(14):1966-1968, September 24, 2004.
Letter
 
          Conference Reports, Abstracts, and Posters
 
  POSTER
 Use of Enfuvirtide in HIV+ Pregnant Women
 A Haberl, R Linde, A Reitter, et al
 PDF Poster     Abstract
Terumo SurGuard2
       

          Internet Documents

  PDF FACT SHEET
 Fact Sheet: New Safety Syringe in Fuzeon Convenience Kit
 Roche/ Trimeris
October 2005
Biojector
       
  News
 
  PDF NEWS RELEASE
 FDA Issues Approvable Letter for Biojector Needle-Free Injection Device for FUZEON
Roche/ Trimeris
November 23, 2005
News Release
 
  Journal Papers, Abstracts and Commentates
 
 
An Open-Label Safety Study of Enfuvirtide Injection with a Needle-Free Injection Device or Needle/Syringe:
The Biojector 2000 Open-Label Safety Study (BOSS).
 Lalezari JP, Saag M, Walworth C, Larson P.
 AIDS Res Hum Retroviruses. 2008 May 28.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Enfuvirtide plasma levels and injection site reactions using a needle-free
gas-powered injection system (Biojector).
 Harris M, Joy R, Larsen G, Valyi M, et al
AIDS. 2006 Mar 21;20(5):719-23.
Abstract

ARV Drugs Main Page Main New/Newsworthy Home Page      

Enfuvirtide